C

Celon Pharma SA
WSE:CLN

Watchlist Manager
Celon Pharma SA
WSE:CLN
Watchlist
Price: 26.6 PLN 2.31% Market Closed
Market Cap: 1.4B PLN
Have any thoughts about
Celon Pharma SA?
Write Note

Celon Pharma SA
Non-Reccuring Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Celon Pharma SA
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
C
Celon Pharma SA
WSE:CLN
Non-Reccuring Items
zł668k
CAGR 3-Years
59%
CAGR 5-Years
12%
CAGR 10-Years
N/A
M
Molecure SA
WSE:MOC
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Cannabis Poland SA
WSE:CBD
Non-Reccuring Items
-zł140.5k
CAGR 3-Years
-5%
CAGR 5-Years
49%
CAGR 10-Years
N/A
No Stocks Found

Celon Pharma SA
Glance View

Market Cap
1.4B PLN
Industry
Pharmaceuticals

Celon Pharma SA is a pharmaceutical company, which engages in the research and manufacture of modern drugs. The firm focuses on research, development and production of generic drugs for cancer, neurological diseases, diabetes and other metabolic disorders treatment, among others. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir and Valzek, as well as inhalation powder, such as Salmex. The firm's research center develops pharmaceuticals within a number of therapeutic areas, including oncology, neurology, as well as inflammatory and metabolic diseases. The firm is a subsidiary of Glatton sp z o o.

CLN Intrinsic Value
8.66 PLN
Overvaluation 67%
Intrinsic Value
Price
C

See Also

What is Celon Pharma SA's Non-Reccuring Items?
Non-Reccuring Items
668k PLN

Based on the financial report for Jun 30, 2024, Celon Pharma SA's Non-Reccuring Items amounts to 668k PLN.

What is Celon Pharma SA's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 5Y
12%

Over the last year, the Non-Reccuring Items growth was -28%. The average annual Non-Reccuring Items growth rates for Celon Pharma SA have been 59% over the past three years , 12% over the past five years .

Back to Top